Ikarian Capital’s bluebird bio BLUE Stock Holding History

Ikarian Capital’s Portfolio BLUE Stock Details BLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-20,631	Closed	-$1.36M	–	152
2023 Q2	$1.36M	Hold	20,631	–	–	0.22%	78
2023 Q1	$1.31M	Sell	20,631 -20,000	-49%	-$2.28M	0.3%	66
2022 Q4	$5.62M	Buy	40,631 +17,500	+76%	+$2.47M	1.36%	25
2022 Q3	$2.93M	Buy	+23,131	New	+$2.62M	0.58%	51
2022 Q2	–	Sell	-15	Closed	-$1K	–	153
2022 Q1	$1K	Buy	15 +1	+7%	+$132	﹤0.01%	195
2021 Q4	$2K	Buy	+14	New	+$3.3K	﹤0.01%	185
2021 Q2	–	Sell	-22	Closed	-$8K	–	227
2021 Q1	$8K	Hold	22	–	–	﹤0.01%	290
2020 Q4	$12K	Sell	22 -3,088	-99%	-$1.96M	﹤0.01%	225
2020 Q3	$2.17M	Sell	3,110 -4,986	-62%	-$3.89M	0.16%	109
2020 Q2	$6.4M	Buy	8,096 +7,594	+1,513%	+$5.73M	0.51%	60
2020 Q1	$299K	Buy	+502	New	+$489K	0.02%	140

Other funds holding BLUE

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Ikarian Capital's BLUE Position: Q3 2023 in Review

Ikarian Capital sold out of bluebird bio (BLUE) in Q3 2023, closing a stake of 20,631 shares — an estimated $1.36M sold.

Ikarian Capital first reported a position in BLUE in Q1 2020 and held it in 11 quarters. The position peaked at $6.4M in Q2 2020. 168 funds tracked by Wall St. Rank hold BLUE as of Q3 2023.

Ikarian Capital reported no remaining bluebird bio position as of Q3 2023 after selling out during the quarter.
Ikarian Capital sold 20,631 bluebird bio shares in Q3 2023, an estimated $1.36M.
Ikarian Capital first reported a position in bluebird bio in Q1 2020 and held it in 11 quarters.
Ikarian Capital's bluebird bio position peaked at $6.4M in Q2 2020.
168 funds tracked by Wall St. Rank held bluebird bio as of Q3 2023.

Based on Ikarian Capital's 13F filing for Q3 2023, filed 14 Nov 2023.